Genedrive (GDR) H2 2025 earnings summary

Executive summary

• Provides rapid pharmacogenetic testing for emergency healthcare, with two CE-IVD-certified products addressing antibiotic-induced hearing loss in neonates and clopidogrel resistance in stroke/cardiovascular patients, co-developed with NHS partners.

• Both products are recommended by NICE, have strong clinical guidance, and are in routine clinical use in early adopter hospitals, showing early commercial traction in the UK and internationally.

• Company operates a capital-light, outsourced manufacturing model, supporting scalability and recurring revenue.

Financial highlights

• FY25 total income reached GBP 1 million, up from GBP 50k in 2023 and GBP 501k in FY24, with revenue from customer contracts at GBP 764k.

• Loss before tax improved to GBP 5.4 million from GBP 7.8 million in FY24, while operating loss for FY25 was GBP 5.38 million.

• Net cash outflow for the year was GBP 4 million, with cash at end of FY25 at GBP 1.18 million, down from GBP 5.19 million at the start of the year.

• Monthly cash burn reduced to GBP 350,000 in the current year, with an average of GBP 468,000 in FY25.

• Equity investment of GBP 1.23 million received in April 2025.

Outlook and guidance

• Well positioned to capitalize on growing demand for near-patient pharmacogenetic testing in emergency care, with no direct competitors offering equivalent solutions.

• Ongoing phased implementation in Scotland and pilot programs in Saudi Arabia, with potential for national rollouts.

• Regulatory submissions for U.S. market on track, with CYP2C19 510(k) submission expected late Q4 FY26 and MT-RNR1 de novo submission targeted for end of 2026.

• Recurring revenue potential with expanding domestic and international commercial traction.